TTR and cardiac amyloidosis: Other therapies have been attempted in ATTR-CM, such as the use of TTR degraders with the combination of doxycycline and tauroursodeoxycholic acid (TUDCA) [266], or are being studied, including anti-monoclonal antibody targeting TTR deposits in patients with TTR cardiac amyloidosis (NCT04360434).